Long-term efficacy and safety of vestronidase alfa enzyme replacement therapy in pediatric subjects < 5 years with mucopolysaccharidosis VII
Mucopolysaccharidosis (MPS) VII is an ultra-rare, autosomal-recessive, metabolic disease caused by a deficiency of β-glucuronidase, a lysosomal enzyme that hydrolyzes glycosaminoglycans (GAGs), including dermatan sulfate (DS), chondroitin sulfate, and heparan sulfate (HS). β-glucuronidase deficiency...
Saved in:
| Published in: | Molecular genetics and metabolism Vol. 136; no. 1; pp. 28 - 37 |
|---|---|
| Main Authors: | , , , , , , , , , |
| Format: | Journal Article |
| Language: | English |
| Published: |
United States
Elsevier Inc
01.05.2022
|
| Subjects: | |
| ISSN: | 1096-7192, 1096-7206, 1096-7206 |
| Online Access: | Get full text |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Abstract | Mucopolysaccharidosis (MPS) VII is an ultra-rare, autosomal-recessive, metabolic disease caused by a deficiency of β-glucuronidase, a lysosomal enzyme that hydrolyzes glycosaminoglycans (GAGs), including dermatan sulfate (DS), chondroitin sulfate, and heparan sulfate (HS). β-glucuronidase deficiency leads to progressive accumulation of undegraded GAGs in lysosomes of affected tissues, which may cause hydrops fetalis, short stature, hepatosplenomegaly, and cognitive impairment.
An open-label, multicenter, phase II study was conducted in 8 pediatric subjects <5 years of age with MPS VII. Subjects received the recombinant human β-glucuronidase vestronidase alfa 4 mg/kg by intravenous infusion every other week for 48 weeks (treatment period). Those who completed the 48-week treatment were offered to continue treatment with vestronidase alfa 4 mg/kg for up to 240 weeks or until withdrawal of consent, discontinuation, or study termination (continuation period).
The level of GAG excreted in urine (uGAG) above normal has been shown to correlate with disease severity and clinical outcomes in MPS diseases. Therefore, the primary efficacy endpoint of this study was to determine the mean percentage change in uGAG DS excretion from baseline to week 48. Statistically significant reductions in uGAG DS from baseline were observed at each visit (p < 0.0001), with a least square mean (standard error) percentage change of −60% (6.6) at week 4 (first post-baseline assessment) and −61% (6.41) at week 48 (final assessment during treatment period). Secondary efficacy endpoints included change from baseline to week 48 in growth and hepatosplenomegaly. Positive trends were observed toward increased standing height Z-score (mean [standard deviation] at baseline, −2.630 [1.17], n = 8; at week 48, −2.045 [0.27], n = 7) and growth velocity (mean [SD] Z-score at baseline, −2.59 [1.49], n = 4; at week 48, −0.39 [2.10], n = 4; p = 0.27). Hepatomegaly was resolved in 3 of 3 subjects assessed by ultrasound and in 5 of 6 subjects assessed by physical examination; splenomegaly was resolved in 1 of 3 subjects assessed by ultrasound and in 2 of 2 subjects assessed by physical examination. There were no new safety signals identified during this study. Mild-to-moderate infusion-associated reactions occurred in 4 (50%) subjects.
In conclusion, long-term vestronidase alfa treatment demonstrated a rapid and sustained reduction in uGAGs, maintained growth, and improved hepatosplenomegaly in pediatric subjects with MPS VII <5 years of age.
Trial registration: NCT02418455. |
|---|---|
| AbstractList | Mucopolysaccharidosis (MPS) VII is an ultra-rare, autosomal-recessive, metabolic disease caused by a deficiency of β-glucuronidase, a lysosomal enzyme that hydrolyzes glycosaminoglycans (GAGs), including dermatan sulfate (DS), chondroitin sulfate, and heparan sulfate (HS). β-glucuronidase deficiency leads to progressive accumulation of undegraded GAGs in lysosomes of affected tissues, which may cause hydrops fetalis, short stature, hepatosplenomegaly, and cognitive impairment. An open-label, multicenter, phase II study was conducted in 8 pediatric subjects <5 years of age with MPS VII. Subjects received the recombinant human β-glucuronidase vestronidase alfa 4 mg/kg by intravenous infusion every other week for 48 weeks (treatment period). Those who completed the 48-week treatment were offered to continue treatment with vestronidase alfa 4 mg/kg for up to 240 weeks or until withdrawal of consent, discontinuation, or study termination (continuation period). The level of GAG excreted in urine (uGAG) above normal has been shown to correlate with disease severity and clinical outcomes in MPS diseases. Therefore, the primary efficacy endpoint of this study was to determine the mean percentage change in uGAG DS excretion from baseline to week 48. Statistically significant reductions in uGAG DS from baseline were observed at each visit (p < 0.0001), with a least square mean (standard error) percentage change of -60% (6.6) at week 4 (first post-baseline assessment) and -61% (6.41) at week 48 (final assessment during treatment period). Secondary efficacy endpoints included change from baseline to week 48 in growth and hepatosplenomegaly. Positive trends were observed toward increased standing height Z-score (mean [standard deviation] at baseline, -2.630 [1.17], n = 8; at week 48, -2.045 [0.27], n = 7) and growth velocity (mean [SD] Z-score at baseline, -2.59 [1.49], n = 4; at week 48, -0.39 [2.10], n = 4; p = 0.27). Hepatomegaly was resolved in 3 of 3 subjects assessed by ultrasound and in 5 of 6 subjects assessed by physical examination; splenomegaly was resolved in 1 of 3 subjects assessed by ultrasound and in 2 of 2 subjects assessed by physical examination. There were no new safety signals identified during this study. Mild-to-moderate infusion-associated reactions occurred in 4 (50%) subjects. In conclusion, long-term vestronidase alfa treatment demonstrated a rapid and sustained reduction in uGAGs, maintained growth, and improved hepatosplenomegaly in pediatric subjects with MPS VII <5 years of age. Trial registration: NCT02418455. Mucopolysaccharidosis (MPS) VII is an ultra-rare, autosomal-recessive, metabolic disease caused by a deficiency of β-glucuronidase, a lysosomal enzyme that hydrolyzes glycosaminoglycans (GAGs), including dermatan sulfate (DS), chondroitin sulfate, and heparan sulfate (HS). β-glucuronidase deficiency leads to progressive accumulation of undegraded GAGs in lysosomes of affected tissues, which may cause hydrops fetalis, short stature, hepatosplenomegaly, and cognitive impairment. An open-label, multicenter, phase II study was conducted in 8 pediatric subjects <5 years of age with MPS VII. Subjects received the recombinant human β-glucuronidase vestronidase alfa 4 mg/kg by intravenous infusion every other week for 48 weeks (treatment period). Those who completed the 48-week treatment were offered to continue treatment with vestronidase alfa 4 mg/kg for up to 240 weeks or until withdrawal of consent, discontinuation, or study termination (continuation period). The level of GAG excreted in urine (uGAG) above normal has been shown to correlate with disease severity and clinical outcomes in MPS diseases. Therefore, the primary efficacy endpoint of this study was to determine the mean percentage change in uGAG DS excretion from baseline to week 48. Statistically significant reductions in uGAG DS from baseline were observed at each visit (p < 0.0001), with a least square mean (standard error) percentage change of −60% (6.6) at week 4 (first post-baseline assessment) and −61% (6.41) at week 48 (final assessment during treatment period). Secondary efficacy endpoints included change from baseline to week 48 in growth and hepatosplenomegaly. Positive trends were observed toward increased standing height Z-score (mean [standard deviation] at baseline, −2.630 [1.17], n = 8; at week 48, −2.045 [0.27], n = 7) and growth velocity (mean [SD] Z-score at baseline, −2.59 [1.49], n = 4; at week 48, −0.39 [2.10], n = 4; p = 0.27). Hepatomegaly was resolved in 3 of 3 subjects assessed by ultrasound and in 5 of 6 subjects assessed by physical examination; splenomegaly was resolved in 1 of 3 subjects assessed by ultrasound and in 2 of 2 subjects assessed by physical examination. There were no new safety signals identified during this study. Mild-to-moderate infusion-associated reactions occurred in 4 (50%) subjects. In conclusion, long-term vestronidase alfa treatment demonstrated a rapid and sustained reduction in uGAGs, maintained growth, and improved hepatosplenomegaly in pediatric subjects with MPS VII <5 years of age. Trial registration: NCT02418455. Mucopolysaccharidosis (MPS) VII is an ultra-rare, autosomal-recessive, metabolic disease caused by a deficiency of β-glucuronidase, a lysosomal enzyme that hydrolyzes glycosaminoglycans (GAGs), including dermatan sulfate (DS), chondroitin sulfate, and heparan sulfate (HS). β-glucuronidase deficiency leads to progressive accumulation of undegraded GAGs in lysosomes of affected tissues, which may cause hydrops fetalis, short stature, hepatosplenomegaly, and cognitive impairment. An open-label, multicenter, phase II study was conducted in 8 pediatric subjects <5 years of age with MPS VII. Subjects received the recombinant human β-glucuronidase vestronidase alfa 4 mg/kg by intravenous infusion every other week for 48 weeks (treatment period). Those who completed the 48-week treatment were offered to continue treatment with vestronidase alfa 4 mg/kg for up to 240 weeks or until withdrawal of consent, discontinuation, or study termination (continuation period). The level of GAG excreted in urine (uGAG) above normal has been shown to correlate with disease severity and clinical outcomes in MPS diseases. Therefore, the primary efficacy endpoint of this study was to determine the mean percentage change in uGAG DS excretion from baseline to week 48. Statistically significant reductions in uGAG DS from baseline were observed at each visit (p < 0.0001), with a least square mean (standard error) percentage change of -60% (6.6) at week 4 (first post-baseline assessment) and -61% (6.41) at week 48 (final assessment during treatment period). Secondary efficacy endpoints included change from baseline to week 48 in growth and hepatosplenomegaly. Positive trends were observed toward increased standing height Z-score (mean [standard deviation] at baseline, -2.630 [1.17], n = 8; at week 48, -2.045 [0.27], n = 7) and growth velocity (mean [SD] Z-score at baseline, -2.59 [1.49], n = 4; at week 48, -0.39 [2.10], n = 4; p = 0.27). Hepatomegaly was resolved in 3 of 3 subjects assessed by ultrasound and in 5 of 6 subjects assessed by physical examination; splenomegaly was resolved in 1 of 3 subjects assessed by ultrasound and in 2 of 2 subjects assessed by physical examination. There were no new safety signals identified during this study. Mild-to-moderate infusion-associated reactions occurred in 4 (50%) subjects. In conclusion, long-term vestronidase alfa treatment demonstrated a rapid and sustained reduction in uGAGs, maintained growth, and improved hepatosplenomegaly in pediatric subjects with MPS VII <5 years of age. Trial registration: NCT02418455.Mucopolysaccharidosis (MPS) VII is an ultra-rare, autosomal-recessive, metabolic disease caused by a deficiency of β-glucuronidase, a lysosomal enzyme that hydrolyzes glycosaminoglycans (GAGs), including dermatan sulfate (DS), chondroitin sulfate, and heparan sulfate (HS). β-glucuronidase deficiency leads to progressive accumulation of undegraded GAGs in lysosomes of affected tissues, which may cause hydrops fetalis, short stature, hepatosplenomegaly, and cognitive impairment. An open-label, multicenter, phase II study was conducted in 8 pediatric subjects <5 years of age with MPS VII. Subjects received the recombinant human β-glucuronidase vestronidase alfa 4 mg/kg by intravenous infusion every other week for 48 weeks (treatment period). Those who completed the 48-week treatment were offered to continue treatment with vestronidase alfa 4 mg/kg for up to 240 weeks or until withdrawal of consent, discontinuation, or study termination (continuation period). The level of GAG excreted in urine (uGAG) above normal has been shown to correlate with disease severity and clinical outcomes in MPS diseases. Therefore, the primary efficacy endpoint of this study was to determine the mean percentage change in uGAG DS excretion from baseline to week 48. Statistically significant reductions in uGAG DS from baseline were observed at each visit (p < 0.0001), with a least square mean (standard error) percentage change of -60% (6.6) at week 4 (first post-baseline assessment) and -61% (6.41) at week 48 (final assessment during treatment period). Secondary efficacy endpoints included change from baseline to week 48 in growth and hepatosplenomegaly. Positive trends were observed toward increased standing height Z-score (mean [standard deviation] at baseline, -2.630 [1.17], n = 8; at week 48, -2.045 [0.27], n = 7) and growth velocity (mean [SD] Z-score at baseline, -2.59 [1.49], n = 4; at week 48, -0.39 [2.10], n = 4; p = 0.27). Hepatomegaly was resolved in 3 of 3 subjects assessed by ultrasound and in 5 of 6 subjects assessed by physical examination; splenomegaly was resolved in 1 of 3 subjects assessed by ultrasound and in 2 of 2 subjects assessed by physical examination. There were no new safety signals identified during this study. Mild-to-moderate infusion-associated reactions occurred in 4 (50%) subjects. In conclusion, long-term vestronidase alfa treatment demonstrated a rapid and sustained reduction in uGAGs, maintained growth, and improved hepatosplenomegaly in pediatric subjects with MPS VII <5 years of age. Trial registration: NCT02418455. |
| Author | Malkus, Betsy Tanpaiboon, Pranoot Martins, Esmeralda Jurecka, Agnieszka Lopez, Antonio Gonzalez-Meneses Viskochil, David Lau, Heather A. Taylor, Julie Zhang, Lin Marsden, Deborah |
| Author_xml | – sequence: 1 givenname: Heather A. surname: Lau fullname: Lau, Heather A. email: Heather.Lau@nyulangone.org organization: NYU Grossman School of Medicine, Department of Neurology, New York, NY, USA – sequence: 2 givenname: David surname: Viskochil fullname: Viskochil, David email: Dave.Viskochil@hsc.utah.edu organization: University of Utah, Department of Pediatrics, Salt Lake City, UT, USA – sequence: 3 givenname: Pranoot surname: Tanpaiboon fullname: Tanpaiboon, Pranoot email: PTanpaib@childrensnational.org organization: Rare Disease Institute, Children's National Health System, Washington, DC, USA – sequence: 4 givenname: Antonio Gonzalez-Meneses surname: Lopez fullname: Lopez, Antonio Gonzalez-Meneses email: antonio.gonzalezmeneses.l.sspa@juntadeandalucia.es organization: Hospital Universitario Virgen del Rocío and Universidad de Sevilla, Seville, Spain – sequence: 5 givenname: Esmeralda surname: Martins fullname: Martins, Esmeralda email: esmeralda.dia@chporto.min-saude.pt organization: Centro Hospitalar Universitário do Porto, Hospital de Santo António, Porto, Portugal – sequence: 6 givenname: Julie surname: Taylor fullname: Taylor, Julie email: JTaylor@ultragenyx.com organization: Ultragenyx Pharmaceutical Inc., Novato, CA, USA – sequence: 7 givenname: Betsy surname: Malkus fullname: Malkus, Betsy email: BMalkus@ultragenyx.com organization: Ultragenyx Pharmaceutical Inc., Novato, CA, USA – sequence: 8 givenname: Lin surname: Zhang fullname: Zhang, Lin email: LZhang@ultragenyx.com organization: Ultragenyx Pharmaceutical Inc., Novato, CA, USA – sequence: 9 givenname: Agnieszka surname: Jurecka fullname: Jurecka, Agnieszka email: ajurecka@gmail.com organization: Ultragenyx Pharmaceutical Inc., Novato, CA, USA – sequence: 10 givenname: Deborah surname: Marsden fullname: Marsden, Deborah email: DMarsden@ultragenyx.com organization: Ultragenyx Pharmaceutical Inc., Novato, CA, USA |
| BackLink | https://www.ncbi.nlm.nih.gov/pubmed/35331634$$D View this record in MEDLINE/PubMed |
| BookMark | eNp9kctu1DAUhi1URC_wBEjISzYJduw4EwkWqOIy0kjdAFvLcY47HsV2sJ1W4Rl4aFyms-miq3MW_3ek8_2X6MwHDwi9paSmhIoPh3p1tw7qhjRNTVhNSPMCXVDSi6priDg77bRvztFlSgdCKG17_gqds5YxKhi_QH93wd9WGaLDYIzVSq9Y-REnZSCvOBh8BynH4O2oEmA1GYXB_1kd4AjzpDQ48BnnPUQ1r9h6PMNoVY5W47QMB9A54Y-4xSuomPC9zXvsFh3mMK1Jab1X0Y4h2YR_bbev0UujpgRvHucV-vn1y4_r79Xu5tv2-vOu0pzwXHUdHUxrxtGwZuwJMWLDRMsUbcnQDwAN7TRQIjrgTHDSM0M2ZtNyCgXTHWdX6P3x7hzD76X8J51NGqZJeQhLko3gvBgWvC_Rd4_RZXAwyjlap-IqTwZLoD8GdAwpRTBS26yyDT5HZSdJiXxoSx7k_7bkQ1uSMFnaKix7wp7OP099OlJQFN1ZiDJpC14X77HolmOwz_L_AKDBsTY |
| CitedBy_id | crossref_primary_10_1017_cts_2023_606 crossref_primary_10_1016_j_omtm_2022_11_006 crossref_primary_10_1016_j_patol_2025_100814 crossref_primary_10_1016_j_ejmg_2024_104933 crossref_primary_10_1016_j_ymgme_2024_108145 |
| Cites_doi | 10.1002/humu.20828 10.1016/j.ymgme.2018.03.004 10.1203/00006450-199606000-00019 10.1172/JCI1773 10.1016/j.clinbiochem.2014.06.012 10.1016/j.ymgme.2018.02.006 10.1016/j.jpeds.2005.12.014 10.1016/S0022-3476(75)80968-1 10.1023/A:1005423222927 10.1016/j.ymgme.2020.06.004 10.1111/j.1651-2227.2011.02385.x 10.1016/S0022-3476(85)80501-1 10.1016/j.ymgme.2012.12.010 10.1001/archpedi.1985.02140030059029 10.1097/01.gim.0000232477.37660.fb 10.1016/j.jpeds.2004.01.046 10.1007/s13312-010-0090-6 10.1002/uog.20371 10.1016/j.ymgme.2020.01.003 10.2214/ajr.157.1.2048509 10.1186/s12881-016-0284-4 10.1542/peds.2008-0635 10.1542/peds.2006-2156 10.1136/jmedgenet-2015-103322 10.1016/j.jpeds.2016.08.033 10.1016/S0022-3476(73)80162-3 10.1056/NEJM200101183440304 10.1111/j.1399-0004.2009.01324.x |
| ContentType | Journal Article |
| Copyright | 2022 The Authors Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved. |
| Copyright_xml | – notice: 2022 The Authors – notice: Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved. |
| DBID | 6I. AAFTH AAYXX CITATION NPM 7X8 |
| DOI | 10.1016/j.ymgme.2022.03.002 |
| DatabaseName | ScienceDirect Open Access Titles Elsevier:ScienceDirect:Open Access CrossRef PubMed MEDLINE - Academic |
| DatabaseTitle | CrossRef PubMed MEDLINE - Academic |
| DatabaseTitleList | PubMed MEDLINE - Academic |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: 7X8 name: MEDLINE - Academic url: https://search.proquest.com/medline sourceTypes: Aggregation Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Anatomy & Physiology Chemistry Biology |
| EISSN | 1096-7206 |
| EndPage | 37 |
| ExternalDocumentID | 35331634 10_1016_j_ymgme_2022_03_002 S1096719222001536 |
| Genre | Journal Article |
| GroupedDBID | --- --K --M -~X .55 .GJ .~1 0R~ 123 1B1 1RT 1~. 1~5 29M 4.4 457 4G. 53G 5RE 5VS 6I. 7-5 71M 8P~ AACTN AAEDT AAEDW AAFTH AAIAV AAIKJ AAKOC AALRI AAOAW AAQFI AAQXK AAXUO ABFNM ABFRF ABGSF ABJNI ABMAC ABUDA ABXDB ABYKQ ACDAQ ACGFO ACGFS ACRLP ADBBV ADEZE ADFGL ADMUD ADUVX AEBSH AEFWE AEHWI AEKER AENEX AFKWA AFTJW AFXIZ AGHFR AGRDE AGUBO AGYEJ AHPSJ AIEXJ AIKHN AITUG AJBFU AJOXV ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ASPBG AVWKF AXJTR AZFZN BKOJK BLXMC CAG COF CS3 DM4 DOVZS DU5 EBS EFBJH EFLBG EJD EO8 EO9 EP2 EP3 F5P FDB FEDTE FGOYB FIRID FNPLU FYGXN G-Q GBLVA HVGLF HZ~ IHE J1W K-O KOM L7B LG5 M41 MO0 N9A O-L O9- OAUVE OZT P-8 P-9 P2P PC. Q38 R2- RIG ROL RPZ SDF SDG SDP SES SEW SPCBC SSU SSZ T5K X7M XPP ZA5 ZGI ZMT ZU3 ~G- ~KM 9DU AATTM AAXKI AAYWO AAYXX ABWVN ACLOT ACRPL ACVFH ADCNI ADNMO AEIPS AEUPX AFJKZ AFPUW AGQPQ AIGII AIIUN AKBMS AKRWK AKYEP ANKPU APXCP CITATION EFKBS ~HD AGCQF AGRNS BNPGV NPM SSH 7X8 |
| ID | FETCH-LOGICAL-c404t-771bf5fddf32d900f683653a150b9bee217ce1067e4364093f08f8541ebf5c743 |
| ISICitedReferencesCount | 5 |
| ISICitedReferencesURI | http://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=Summon&SrcAuth=ProQuest&DestLinkType=CitingArticles&DestApp=WOS_CPL&KeyUT=000806175600004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| ISSN | 1096-7192 1096-7206 |
| IngestDate | Sun Sep 28 02:45:19 EDT 2025 Mon Jul 21 06:00:36 EDT 2025 Sat Nov 29 07:06:31 EST 2025 Tue Nov 18 22:29:50 EST 2025 Fri Feb 23 02:39:48 EST 2024 |
| IsDoiOpenAccess | true |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | NRE Urinary glycosaminoglycan CPAP suppl O2 Growth ERT LS Mucopolysaccharidosis VII CGI-C HS DS LC-MS/MS MPS SD SE ULN Vestronidase alfa NIHF Hepatosplenomegaly SpO2 h BiPAP Pediatric patients GAG m uGAG CS TEAE MS-DS SAE QOW IAR ADA |
| Language | English |
| License | This is an open access article under the CC BY license. Copyright © 2022 The Authors. Published by Elsevier Inc. All rights reserved. |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c404t-771bf5fddf32d900f683653a150b9bee217ce1067e4364093f08f8541ebf5c743 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 |
| OpenAccessLink | https://dx.doi.org/10.1016/j.ymgme.2022.03.002 |
| PMID | 35331634 |
| PQID | 2644016649 |
| PQPubID | 23479 |
| PageCount | 10 |
| ParticipantIDs | proquest_miscellaneous_2644016649 pubmed_primary_35331634 crossref_citationtrail_10_1016_j_ymgme_2022_03_002 crossref_primary_10_1016_j_ymgme_2022_03_002 elsevier_sciencedirect_doi_10_1016_j_ymgme_2022_03_002 |
| PublicationCentury | 2000 |
| PublicationDate | May 2022 2022-05-00 2022-May 20220501 |
| PublicationDateYYYYMMDD | 2022-05-01 |
| PublicationDate_xml | – month: 05 year: 2022 text: May 2022 |
| PublicationDecade | 2020 |
| PublicationPlace | United States |
| PublicationPlace_xml | – name: United States |
| PublicationTitle | Molecular genetics and metabolism |
| PublicationTitleAlternate | Mol Genet Metab |
| PublicationYear | 2022 |
| Publisher | Elsevier Inc |
| Publisher_xml | – name: Elsevier Inc |
| References | Vogler, Sands, Levy, Galvin, Birkenmeier, Sly (bb0080) 1996; 39 Beaudet, DiFerrante, Ferry, Nicols, Mullins (bb0155) 1975; 86 Komosinska-Vassev, Blat, Olczyk, Szeremeta, Jura-Półtorak, Winsz-Szczotka, Klimek, Olczyk (bb0150) 2014; 47 Wang, da Silva Franco, López-Valdez, Martins, Sutton, Whitley, Zhang, Cimms, Marsden, Jurecka, Harmatz (bb0090) 2020; 129 Wraith, Clarke, Beck, Kolodny, Pastores, Muenzer, Rapoport, Berger, Swiedler, Kakkis, Braakman, Chadbourne, Walton-Bowen, Cox (bb0040) 2004; 144 Tomatsu, Montaño, Dung, Grubb, Sly (bb0020) 2009; 30 Lampe, Atherton, Burton, Descartes, Giugliani, Horovitz, Kyosen, Magalhães, Martins, Mendelsohn, Muenzer, Smith (bb0100) 2014; 14 Różdżyńska-Świątkowska, Jurkiewicz, Tylki-Szymańska (bb0060) 2016; 26 Staretz-Chacham, Lang, LaMarca, Krasnewich, Sidransky (bb0170) 2009; 123 McCafferty, Scott (bb0015) 2019; 33 Melbouci, Mason, Suzuki, Fukao, Orii, Tomatsu (bb0055) 2018; 124 Harmatz, Giugliani, Schwartz, Guffon, Teles, Miranda, Wraith, Beck, Arash, Scarpa, Yu, Wittes, Berger, Newman, Lowe, Kakkis, Swiedler, MPS VI Phase 3 Study Group (bb0045) 2006; 148 Tanner, Davies (bb0145) 1985; 107 Sly, Quinton, McAlister, Rimoin (bb0010) 1973; 82 Kakkis, Muenzer, Tiller, Waber, Belmont, Passage, Izykowski, Phillips, Doroshow, Walot, Hoft, Neufeld (bb0030) 2001; 344 Dhingra, Sharma, Mishra, Kumari, Pandey, Aggarwal (bb0130) 2010; 47 Muenzer, Wraith, Beck, Giugliani, Harmatz, Eng, Vellodi, Martin, Ramaswami, Gucsavas-Calikoglu, Vijayaraghavan, Wendt, Puga, Ulbrich, Shinawi, Cleary, Piper, Conway, Kimura (bb0005) 2006; 8 Vervoort, Islam, Sly, Zabot, Kleijer, Chabas, Fensom, Young, Liebaers, Lissens (bb0175) 1996; 58 Gabrielli, Clarke, Ficcadenti, Santoro, Zampini, Volpi, Coppa (bb0095) 2016; 17 Gillett, Schreiber, Jevon, Israel, Warshawski, Vallance, Clarke (bb0160) 2001; 33 Vogler, Sands, Galvin, Levy, Thorpe, Barker, Sly (bb0075) 1998; 21 O’Connor, Erway, Vogler, Sly, Nicholes, Grubb, Holmberg, Levy, Sands (bb0070) 1998; 101 Harmatz, Whitley, Wang, Bauer, Song, Haller, Kakkis (bb0085) 2018; 123 Tylki-Szymanska, Jurecka, Zuber, Rozdzynska, Marucha, Czartoryska (bb0120) 2012; 101 Wraith, Beck, Lane, van der Ploeg, Shapiro, Xue, Kakkis, Guffon (bb0035) 2007; 120 Montaño, Lock-Hock, Steiner, Graham, Szlago, Greenstein, Pineda, Gonzalez-Meneses, Çoker, Bartholomew, Sands, Wang, Giugliani, Macaya, Pastores, Ketko, Ezgü, Tanaka, Arash, Beck, Falk, Bhattacharya, Franco, White, Mitchell, Cimbalistiene, Holtz, Sly (bb0065) 2016; 53 Busner, Targum (bb0135) 2007; 4 Holtz, Montaño, Sly (bb0025) 2020; 55 Laraway, Mercer, Jameson, Ashworth, Hensman, Jones (bb0105) 2016; 178 Rosenberg, Markowitz, Kolberg, Park, Hubbard, Bellah (bb0125) 1991; 157 Bayley (bb0140) 2006 Lee, Falk, Ng, Donnell (bb0165) 1985; 139 Jones, Marsden, Koutsoukos, Sniadecki, Tylee, Phillippo, Kakkis (bb0050) 2020; 130 Tajima, Sakura, Kosuga, Okuyama, Kobayashi (bb0115) 2013; 108 McGill, Inwood, Coman, Lipke, de Lore, Swiedler, Hopwood (bb0110) 2010; 77 Holtz (10.1016/j.ymgme.2022.03.002_bb0025) 2020; 55 Beaudet (10.1016/j.ymgme.2022.03.002_bb0155) 1975; 86 Lampe (10.1016/j.ymgme.2022.03.002_bb0100) 2014; 14 Staretz-Chacham (10.1016/j.ymgme.2022.03.002_bb0170) 2009; 123 Lee (10.1016/j.ymgme.2022.03.002_bb0165) 1985; 139 Kakkis (10.1016/j.ymgme.2022.03.002_bb0030) 2001; 344 McGill (10.1016/j.ymgme.2022.03.002_bb0110) 2010; 77 Busner (10.1016/j.ymgme.2022.03.002_bb0135) 2007; 4 McCafferty (10.1016/j.ymgme.2022.03.002_bb0015) 2019; 33 O’Connor (10.1016/j.ymgme.2022.03.002_bb0070) 1998; 101 Wraith (10.1016/j.ymgme.2022.03.002_bb0040) 2004; 144 Bayley (10.1016/j.ymgme.2022.03.002_bb0140) 2006 Montaño (10.1016/j.ymgme.2022.03.002_bb0065) 2016; 53 Harmatz (10.1016/j.ymgme.2022.03.002_bb0045) 2006; 148 Różdżyńska-Świątkowska (10.1016/j.ymgme.2022.03.002_bb0060) 2016; 26 Tajima (10.1016/j.ymgme.2022.03.002_bb0115) 2013; 108 Gabrielli (10.1016/j.ymgme.2022.03.002_bb0095) 2016; 17 Komosinska-Vassev (10.1016/j.ymgme.2022.03.002_bb0150) 2014; 47 Vogler (10.1016/j.ymgme.2022.03.002_bb0080) 1996; 39 Rosenberg (10.1016/j.ymgme.2022.03.002_bb0125) 1991; 157 Vervoort (10.1016/j.ymgme.2022.03.002_bb0175) 1996; 58 Tomatsu (10.1016/j.ymgme.2022.03.002_bb0020) 2009; 30 Laraway (10.1016/j.ymgme.2022.03.002_bb0105) 2016; 178 Sly (10.1016/j.ymgme.2022.03.002_bb0010) 1973; 82 Melbouci (10.1016/j.ymgme.2022.03.002_bb0055) 2018; 124 Wang (10.1016/j.ymgme.2022.03.002_bb0090) 2020; 129 Jones (10.1016/j.ymgme.2022.03.002_bb0050) 2020; 130 Tanner (10.1016/j.ymgme.2022.03.002_bb0145) 1985; 107 Gillett (10.1016/j.ymgme.2022.03.002_bb0160) 2001; 33 Wraith (10.1016/j.ymgme.2022.03.002_bb0035) 2007; 120 Tylki-Szymanska (10.1016/j.ymgme.2022.03.002_bb0120) 2012; 101 Dhingra (10.1016/j.ymgme.2022.03.002_bb0130) 2010; 47 Muenzer (10.1016/j.ymgme.2022.03.002_bb0005) 2006; 8 Harmatz (10.1016/j.ymgme.2022.03.002_bb0085) 2018; 123 Vogler (10.1016/j.ymgme.2022.03.002_bb0075) 1998; 21 |
| References_xml | – volume: 178 start-page: 219 year: 2016 end-page: 226 ident: bb0105 article-title: Outcomes of long-term treatment with laronidase in patients with mucopolysaccharidosis type I publication-title: J. Pediatr. – volume: 47 start-page: 487 year: 2010 end-page: 492 ident: bb0130 article-title: Normal values of liver and spleen size by ultrasonography in Indian children publication-title: Ind. Pediatr. – volume: 123 start-page: 488 year: 2018 end-page: 494 ident: bb0085 article-title: A novel blind start study design to investigate vestronidase alfa for mucopolysaccharidosis VII, an ultra-rare genetic disease publication-title: Mol. Genet. Metab. – volume: 123 start-page: 1191 year: 2009 end-page: 1207 ident: bb0170 article-title: Lysosomal storage disorders in the newborn publication-title: Pediatrics – volume: 21 start-page: 575 year: 1998 end-page: 586 ident: bb0075 article-title: Murine mucopolysaccharidosis type VII: the impact of therapies on the clinical course and pathology in a murine model of lysosomal storage disease publication-title: J. Inherit. Metab. Dis. – volume: 17 start-page: 19 year: 2016 ident: bb0095 article-title: 12 year follow up of enzyme-replacement therapy in two siblings with attenuated mucopolysaccharidosis I: the important role of early treatment publication-title: BMC Med. Genet. – volume: 8 start-page: 465 year: 2006 end-page: 473 ident: bb0005 article-title: A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome) publication-title: Genet. Med. – volume: 144 start-page: 581 year: 2004 end-page: 588 ident: bb0040 article-title: Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase) publication-title: J. Pediatr. – volume: 58 start-page: 457 year: 1996 end-page: 471 ident: bb0175 article-title: Molecular analysis of patients with beta-glucuronidase deficiency presenting as hydrops fetalis or as early mucopolysaccharidosis VII publication-title: Am. J. Hum. Genet. – volume: 33 start-page: 233 year: 2019 end-page: 240 ident: bb0015 article-title: Vestronidase alfa: a review in mucopolysaccharidosis publication-title: VII BioDrugs – volume: 53 start-page: 403 year: 2016 end-page: 418 ident: bb0065 article-title: Clinical course of Sly syndrome (mucopolysaccharidosis type VII) publication-title: J. Med. Genet. – volume: 157 start-page: 119 year: 1991 end-page: 121 ident: bb0125 article-title: Normal splenic size in infants and children: sonographic measurements publication-title: AJR Am. J. Roentgenol. – volume: 86 start-page: 388 year: 1975 end-page: 394 ident: bb0155 article-title: Variation in the phenotypic expression of β-glucuronidase deficiency publication-title: J. Pediatr. – volume: 129 start-page: 219 year: 2020 end-page: 227 ident: bb0090 article-title: The long-term safety and efficacy of vestronidase alfa, rhGUS enzyme replacement therapy, in subjects with mucopolysaccharidosis VII publication-title: Mol. Genet. Metab. – volume: 33 start-page: 216 year: 2001 end-page: 220 ident: bb0160 article-title: Mucopolysaccharidosis type VII (Sly syndrome) presenting as neonatal cholestasis with hepatosplenomegaly publication-title: J. Pediatr. Gastroenterol. Nutr. – volume: 39 start-page: 1050 year: 1996 end-page: 1054 ident: bb0080 article-title: Enzyme replacement with recombinant beta-glucuronidase in murine mucopolysaccharidosis type VII: impact of therapy during the first six weeks of life on subsequent lysosomal storage, growth, and survival publication-title: Pediatr. Res. – volume: 82 start-page: 249 year: 1973 end-page: 257 ident: bb0010 article-title: Beta glucuronidase deficiency: report of clinical, radiologic, and biochemical features of a new mucopolysaccharidosis publication-title: J. Pediatr. – volume: 4 start-page: 28 year: 2007 end-page: 37 ident: bb0135 article-title: The clinical global impressions scale: applying a research tool in clinical practice publication-title: Psychiatry (Edgmont.) – volume: 77 start-page: 492 year: 2010 end-page: 498 ident: bb0110 article-title: Enzyme replacement therapy for mucopolysaccharidosis VI from 8 weeks of age—a sibling control study publication-title: Clin. Genet. – volume: 108 start-page: 172 year: 2013 end-page: 177 ident: bb0115 article-title: Effects of idursulfase enzyme replacement therapy for mucopolysaccharidosis type II when started in early infancy: comparison in two siblings publication-title: Mol. Genet. Metab. – year: 2006 ident: bb0140 article-title: Bayley Scales of Infant and Toddler Development – volume: 55 start-page: 416 year: 2020 end-page: 417 ident: bb0025 article-title: Association between mucopolysaccharidosis type VII and hydrops fetalis publication-title: Ultrasound Obstet. Gynecol. – volume: 124 start-page: 1 year: 2018 end-page: 10 ident: bb0055 article-title: Growth impairment in mucopolysaccharidoses publication-title: Mol. Genet. Metab. – volume: 26 start-page: 45 year: 2016 end-page: 51 ident: bb0060 article-title: Bioimpedance analysis as a method to evaluate the proportion of fatty and muscle tissues in progressive myopathy in Pompe disease publication-title: JIMD Rep. – volume: 14 start-page: 99 year: 2014 end-page: 113 ident: bb0100 article-title: Enzyme replacement therapy in mucopolysaccharidosis II patients under 1 year of age publication-title: JIMD Rep. – volume: 107 start-page: 317 year: 1985 end-page: 329 ident: bb0145 article-title: Clinical longitudinal standards for height and height velocity for North American children publication-title: J. Pediatr. – volume: 148 start-page: 533 year: 2006 end-page: 539 ident: bb0045 article-title: Enzyme replacement therapy for mucopolysaccharidosis VI: a phase 3, randomized, double-blind, placebo-controlled, multinational study of recombinant human N-acetylgalactosamine 4-sulfatase (recombinant human arylsulfatase B or rhASB) and follow-on, open-label extension study publication-title: J. Pediatr. – volume: 101 start-page: e42 year: 2012 end-page: e47 ident: bb0120 article-title: Enzyme replacement therapy for mucopolysaccharidosis II from 3 months of age: a 3-year follow-up publication-title: Acta Paediatr. – volume: 120 start-page: e37 year: 2007 end-page: e46 ident: bb0035 article-title: Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase) publication-title: Pediatrics – volume: 30 start-page: 511 year: 2009 end-page: 519 ident: bb0020 article-title: Mutations and polymorphisms in GUSB gene in mucopolysaccharidosis VII (Sly syndrome) publication-title: Hum. Mutat. – volume: 101 start-page: 1394 year: 1998 end-page: 1400 ident: bb0070 article-title: Enzyme replacement therapy for murine mucopolysaccharidosis type VII leads to improvements in behavior and auditory function publication-title: J. Clin. Invest. – volume: 130 start-page: 255 year: 2020 end-page: 261 ident: bb0050 article-title: Retrospective chart review of urinary glycosaminoglycan excretion and long-term clinical outcomes of enzyme replacement therapy in patients with mucopolysaccharidoses publication-title: Mol. Genet. Metab. – volume: 139 start-page: 57 year: 1985 end-page: 59 ident: bb0165 article-title: Beta-glucuronidase deficiency. A heterogeneous mucopolysaccharidosis publication-title: Am. J. Dis. Child. – volume: 344 start-page: 182 year: 2001 end-page: 188 ident: bb0030 article-title: Enzyme-replacement therapy in mucopolysaccharidosis I publication-title: N. Engl. J. Med. – volume: 47 start-page: 1341 year: 2014 end-page: 1343 ident: bb0150 article-title: Urinary glycosaminoglycan (uGAG) excretion in healthy pediatric and adolescent population publication-title: Clin. Biochem. – volume: 30 start-page: 511 year: 2009 ident: 10.1016/j.ymgme.2022.03.002_bb0020 article-title: Mutations and polymorphisms in GUSB gene in mucopolysaccharidosis VII (Sly syndrome) publication-title: Hum. Mutat. doi: 10.1002/humu.20828 – volume: 124 start-page: 1 year: 2018 ident: 10.1016/j.ymgme.2022.03.002_bb0055 article-title: Growth impairment in mucopolysaccharidoses publication-title: Mol. Genet. Metab. doi: 10.1016/j.ymgme.2018.03.004 – volume: 58 start-page: 457 year: 1996 ident: 10.1016/j.ymgme.2022.03.002_bb0175 article-title: Molecular analysis of patients with beta-glucuronidase deficiency presenting as hydrops fetalis or as early mucopolysaccharidosis VII publication-title: Am. J. Hum. Genet. – volume: 39 start-page: 1050 year: 1996 ident: 10.1016/j.ymgme.2022.03.002_bb0080 article-title: Enzyme replacement with recombinant beta-glucuronidase in murine mucopolysaccharidosis type VII: impact of therapy during the first six weeks of life on subsequent lysosomal storage, growth, and survival publication-title: Pediatr. Res. doi: 10.1203/00006450-199606000-00019 – volume: 101 start-page: 1394 year: 1998 ident: 10.1016/j.ymgme.2022.03.002_bb0070 article-title: Enzyme replacement therapy for murine mucopolysaccharidosis type VII leads to improvements in behavior and auditory function publication-title: J. Clin. Invest. doi: 10.1172/JCI1773 – volume: 47 start-page: 1341 year: 2014 ident: 10.1016/j.ymgme.2022.03.002_bb0150 article-title: Urinary glycosaminoglycan (uGAG) excretion in healthy pediatric and adolescent population publication-title: Clin. Biochem. doi: 10.1016/j.clinbiochem.2014.06.012 – volume: 123 start-page: 488 year: 2018 ident: 10.1016/j.ymgme.2022.03.002_bb0085 article-title: A novel blind start study design to investigate vestronidase alfa for mucopolysaccharidosis VII, an ultra-rare genetic disease publication-title: Mol. Genet. Metab. doi: 10.1016/j.ymgme.2018.02.006 – volume: 33 start-page: 233 year: 2019 ident: 10.1016/j.ymgme.2022.03.002_bb0015 article-title: Vestronidase alfa: a review in mucopolysaccharidosis – volume: 148 start-page: 533 year: 2006 ident: 10.1016/j.ymgme.2022.03.002_bb0045 publication-title: J. Pediatr. doi: 10.1016/j.jpeds.2005.12.014 – volume: 86 start-page: 388 year: 1975 ident: 10.1016/j.ymgme.2022.03.002_bb0155 article-title: Variation in the phenotypic expression of β-glucuronidase deficiency publication-title: J. Pediatr. doi: 10.1016/S0022-3476(75)80968-1 – volume: 21 start-page: 575 year: 1998 ident: 10.1016/j.ymgme.2022.03.002_bb0075 article-title: Murine mucopolysaccharidosis type VII: the impact of therapies on the clinical course and pathology in a murine model of lysosomal storage disease publication-title: J. Inherit. Metab. Dis. doi: 10.1023/A:1005423222927 – volume: 130 start-page: 255 year: 2020 ident: 10.1016/j.ymgme.2022.03.002_bb0050 article-title: Retrospective chart review of urinary glycosaminoglycan excretion and long-term clinical outcomes of enzyme replacement therapy in patients with mucopolysaccharidoses publication-title: Mol. Genet. Metab. doi: 10.1016/j.ymgme.2020.06.004 – volume: 26 start-page: 45 year: 2016 ident: 10.1016/j.ymgme.2022.03.002_bb0060 article-title: Bioimpedance analysis as a method to evaluate the proportion of fatty and muscle tissues in progressive myopathy in Pompe disease publication-title: JIMD Rep. – volume: 101 start-page: e42 year: 2012 ident: 10.1016/j.ymgme.2022.03.002_bb0120 article-title: Enzyme replacement therapy for mucopolysaccharidosis II from 3 months of age: a 3-year follow-up publication-title: Acta Paediatr. doi: 10.1111/j.1651-2227.2011.02385.x – volume: 14 start-page: 99 year: 2014 ident: 10.1016/j.ymgme.2022.03.002_bb0100 article-title: Enzyme replacement therapy in mucopolysaccharidosis II patients under 1 year of age publication-title: JIMD Rep. – volume: 107 start-page: 317 year: 1985 ident: 10.1016/j.ymgme.2022.03.002_bb0145 article-title: Clinical longitudinal standards for height and height velocity for North American children publication-title: J. Pediatr. doi: 10.1016/S0022-3476(85)80501-1 – volume: 108 start-page: 172 year: 2013 ident: 10.1016/j.ymgme.2022.03.002_bb0115 article-title: Effects of idursulfase enzyme replacement therapy for mucopolysaccharidosis type II when started in early infancy: comparison in two siblings publication-title: Mol. Genet. Metab. doi: 10.1016/j.ymgme.2012.12.010 – volume: 139 start-page: 57 year: 1985 ident: 10.1016/j.ymgme.2022.03.002_bb0165 article-title: Beta-glucuronidase deficiency. A heterogeneous mucopolysaccharidosis publication-title: Am. J. Dis. Child. doi: 10.1001/archpedi.1985.02140030059029 – volume: 8 start-page: 465 year: 2006 ident: 10.1016/j.ymgme.2022.03.002_bb0005 article-title: A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopolysaccharidosis II (Hunter syndrome) publication-title: Genet. Med. doi: 10.1097/01.gim.0000232477.37660.fb – volume: 144 start-page: 581 year: 2004 ident: 10.1016/j.ymgme.2022.03.002_bb0040 article-title: Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human alpha-L-iduronidase (laronidase) publication-title: J. Pediatr. doi: 10.1016/j.jpeds.2004.01.046 – volume: 47 start-page: 487 year: 2010 ident: 10.1016/j.ymgme.2022.03.002_bb0130 article-title: Normal values of liver and spleen size by ultrasonography in Indian children publication-title: Ind. Pediatr. doi: 10.1007/s13312-010-0090-6 – volume: 55 start-page: 416 year: 2020 ident: 10.1016/j.ymgme.2022.03.002_bb0025 article-title: Association between mucopolysaccharidosis type VII and hydrops fetalis publication-title: Ultrasound Obstet. Gynecol. doi: 10.1002/uog.20371 – volume: 129 start-page: 219 year: 2020 ident: 10.1016/j.ymgme.2022.03.002_bb0090 article-title: The long-term safety and efficacy of vestronidase alfa, rhGUS enzyme replacement therapy, in subjects with mucopolysaccharidosis VII publication-title: Mol. Genet. Metab. doi: 10.1016/j.ymgme.2020.01.003 – volume: 157 start-page: 119 year: 1991 ident: 10.1016/j.ymgme.2022.03.002_bb0125 article-title: Normal splenic size in infants and children: sonographic measurements publication-title: AJR Am. J. Roentgenol. doi: 10.2214/ajr.157.1.2048509 – volume: 33 start-page: 216 year: 2001 ident: 10.1016/j.ymgme.2022.03.002_bb0160 article-title: Mucopolysaccharidosis type VII (Sly syndrome) presenting as neonatal cholestasis with hepatosplenomegaly publication-title: J. Pediatr. Gastroenterol. Nutr. – volume: 17 start-page: 19 year: 2016 ident: 10.1016/j.ymgme.2022.03.002_bb0095 article-title: 12 year follow up of enzyme-replacement therapy in two siblings with attenuated mucopolysaccharidosis I: the important role of early treatment publication-title: BMC Med. Genet. doi: 10.1186/s12881-016-0284-4 – volume: 123 start-page: 1191 year: 2009 ident: 10.1016/j.ymgme.2022.03.002_bb0170 article-title: Lysosomal storage disorders in the newborn publication-title: Pediatrics doi: 10.1542/peds.2008-0635 – volume: 120 start-page: e37 year: 2007 ident: 10.1016/j.ymgme.2022.03.002_bb0035 article-title: Enzyme replacement therapy in patients who have mucopolysaccharidosis I and are younger than 5 years: results of a multinational study of recombinant human alpha-L-iduronidase (laronidase) publication-title: Pediatrics doi: 10.1542/peds.2006-2156 – volume: 53 start-page: 403 year: 2016 ident: 10.1016/j.ymgme.2022.03.002_bb0065 article-title: Clinical course of Sly syndrome (mucopolysaccharidosis type VII) publication-title: J. Med. Genet. doi: 10.1136/jmedgenet-2015-103322 – volume: 178 start-page: 219 year: 2016 ident: 10.1016/j.ymgme.2022.03.002_bb0105 article-title: Outcomes of long-term treatment with laronidase in patients with mucopolysaccharidosis type I publication-title: J. Pediatr. doi: 10.1016/j.jpeds.2016.08.033 – volume: 82 start-page: 249 year: 1973 ident: 10.1016/j.ymgme.2022.03.002_bb0010 article-title: Beta glucuronidase deficiency: report of clinical, radiologic, and biochemical features of a new mucopolysaccharidosis publication-title: J. Pediatr. doi: 10.1016/S0022-3476(73)80162-3 – volume: 344 start-page: 182 year: 2001 ident: 10.1016/j.ymgme.2022.03.002_bb0030 article-title: Enzyme-replacement therapy in mucopolysaccharidosis I publication-title: N. Engl. J. Med. doi: 10.1056/NEJM200101183440304 – volume: 77 start-page: 492 year: 2010 ident: 10.1016/j.ymgme.2022.03.002_bb0110 article-title: Enzyme replacement therapy for mucopolysaccharidosis VI from 8 weeks of age—a sibling control study publication-title: Clin. Genet. doi: 10.1111/j.1399-0004.2009.01324.x – year: 2006 ident: 10.1016/j.ymgme.2022.03.002_bb0140 – volume: 4 start-page: 28 year: 2007 ident: 10.1016/j.ymgme.2022.03.002_bb0135 article-title: The clinical global impressions scale: applying a research tool in clinical practice publication-title: Psychiatry (Edgmont.) |
| SSID | ssj0011594 |
| Score | 2.376392 |
| Snippet | Mucopolysaccharidosis (MPS) VII is an ultra-rare, autosomal-recessive, metabolic disease caused by a deficiency of β-glucuronidase, a lysosomal enzyme that... |
| SourceID | proquest pubmed crossref elsevier |
| SourceType | Aggregation Database Index Database Enrichment Source Publisher |
| StartPage | 28 |
| SubjectTerms | Growth Hepatosplenomegaly Mucopolysaccharidosis VII Pediatric patients Urinary glycosaminoglycan Vestronidase alfa |
| Title | Long-term efficacy and safety of vestronidase alfa enzyme replacement therapy in pediatric subjects < 5 years with mucopolysaccharidosis VII |
| URI | https://dx.doi.org/10.1016/j.ymgme.2022.03.002 https://www.ncbi.nlm.nih.gov/pubmed/35331634 https://www.proquest.com/docview/2644016649 |
| Volume | 136 |
| WOSCitedRecordID | wos000806175600004&url=https%3A%2F%2Fcvtisr.summon.serialssolutions.com%2F%23%21%2Fsearch%3Fho%3Df%26include.ft.matches%3Dt%26l%3Dnull%26q%3D |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| journalDatabaseRights | – providerCode: PRVESC databaseName: ScienceDirect database customDbUrl: eissn: 1096-7206 dateEnd: 99991231 omitProxy: false ssIdentifier: ssj0011594 issn: 1096-7192 databaseCode: AIEXJ dateStart: 19980101 isFulltext: true titleUrlDefault: https://www.sciencedirect.com providerName: Elsevier |
| link | http://cvtisr.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwtV3bbtNAEF2lLQheELRcwqVaJODFOHLstWNLvISoQFBbVaJUebPW9rpyiO2oTqom38C_8gvM7HrdhNIKkHiJLCeOnZzj3Zn1mTOEvIoclngQKpsJE8xkHG4p33J9M4osjweWLYQnC4X3e4eH_mgUHLVaP3QtzPmkVxT-xUUw_a9Qwz4AG0tn_wLu5kthB2wD6PAKsMPrHwG_XxanJg64qNUACGLlsFTxVCj1BRproCNuAhOYwScpN0SxXOTYP0UqtKQ8QNVlLZTIvO7mYVTzaCzVH6-dgeEaC_jr6uq4fB5jt4VFxWOs48qSEo1OTobD1eD3QLfixb7NovGHzsUMmDjRXobSBXKupkQZnhr9jn7jJKu-lVh__oscH1ceiinPIGWQo-gRzMBl2Sh69supWijvY8fkrDQ-lsUSZsaleYBDvVhb-4C0uVEaqgU5XZSzphntQlZm9rqqxV5HrOyzLW9t4FfWK2sMr4dxfyUgUKY0V6Yateox7izy0xz9Vm1bueXalzNro3f8gufHS7JRwuY63gbZsntuAMPwVn-4N_rcPPiC6FIKIfRv0EZZUpJ45VTXBVPXJUsyaDq-T-7V2Q7tK5Y-IC1RbJOdfsFnZb6gb6jUH8sHO9vk9nu9dWeguxDukO8NnammMwXSUEVnWqZ0lc4U6UwVnekKnWlNZ5oVtKEz1XSm76hLJZkpkpn-lswUyPyQfP2wdzz4ZNYdRMyYWWwGqWM3St00SVLHTgLLSj3f8VyHQxYUBZEQkI_HAk0UBXM8ZgVOavmp77KugMNiCK4fkc2iLMQTQgOfM8EhW7cczuKuH3GX9ZIkYBGEzABam9gaijCu7fWxy8sk1DrKcSjxCxG_0HJCwK9N3jYHTZW7zM0f9zTGYR0gq8A3BFLefOBLzYgQ8MNngrwQ5bwKMR-CgzwWtMljRZXmShxIBSFdY0__9bTPyN3Lu_Y52ZydzcULcis-n2XV2S7Z6I383foG-Akn5PxK |
| linkProvider | Elsevier |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Long-term+efficacy+and+safety+of+vestronidase+alfa+enzyme+replacement+therapy+in+pediatric+subjects+%3C+5+years+with+mucopolysaccharidosis+VII&rft.jtitle=Molecular+genetics+and+metabolism&rft.au=Lau%2C+Heather+A.&rft.au=Viskochil%2C+David&rft.au=Tanpaiboon%2C+Pranoot&rft.au=Lopez%2C+Antonio+Gonzalez-Meneses&rft.date=2022-05-01&rft.pub=Elsevier+Inc&rft.issn=1096-7192&rft.eissn=1096-7206&rft.volume=136&rft.issue=1&rft.spage=28&rft.epage=37&rft_id=info:doi/10.1016%2Fj.ymgme.2022.03.002&rft.externalDocID=S1096719222001536 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=1096-7192&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=1096-7192&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=1096-7192&client=summon |